Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here is What Hedge Funds Think About Pacific Biosciences of California (PACB)

Page 1 of 2

Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors’ favor when it comes to beating the market, as evidenced by the fact that less than 49% of the stocks in the S&P 500 did so during the 12-month period ending October 30. However, 63% of hedge funds’ top 30 stock picks from the index did beat the market, and returned nearly twice as much on average as the index. Thus, we can see that the tireless research and efforts of hedge funds to identify winning stocks can work to our advantage when we know how to use the data. While not all of their picks will be winners, our odds are much better following their best stock picks than trying to go it alone.

Pacific Biosciences of California (NASDAQ:PACB) investors should pay attention to a decrease in hedge fund sentiment lately. PACB was in 11 hedge funds’ portfolios at the end of the third quarter of 2015. There were 15 hedge funds in our database with PACB holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Ameresco Inc (NYSE:AMRC), CTC Media, Inc. (NASDAQ:CTCM), and Heritage Oaks Bancorp (NASDAQ:HEOP) to gather more data points.

Follow Pacific Biosciences Of California Inc. (NASDAQ:PACB)
Trade (NASDAQ:PACB) Now!

In the eyes of most market participants, hedge funds are viewed as unimportant, outdated investment tools of years past. While there are more than 8000 funds trading at the moment, We hone in on the top tier of this group, about 700 funds. These money managers have their hands on bulk of all hedge funds’ total asset base, and by watching their top picks, Insider Monkey has figured out several investment strategies that have historically defeated the market. Insider Monkey’s small-cap hedge fund strategy surpassed the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Keeping this in mind, we’re going to take a look at the recent action regarding Pacific Biosciences of California (NASDAQ:PACB).

Hedge fund activity in Pacific Biosciences of California (NASDAQ:PACB)

At Q3’s end, a total of 11 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -27% from one quarter earlier. With hedgies’ capital changing hands, there exists an “upper tier” of notable hedge fund managers who were boosting their holdings significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Lee Ainslie’s Maverick Capital has the most valuable position in Pacific Biosciences of California (NASDAQ:PACB), worth close to $27.3 million, corresponding to 0.5% of its total 13F portfolio. On Maverick Capital’s heels is Consonance Capital Management, managed by Mitchell Blutt, which holds an $22.9 million position; the fund has 3.2% of its 13F portfolio invested in the stock. Remaining hedge funds and institutional investors that hold long positions encompass Israel Englander’s Millennium Management, James E. Flynn’s Deerfield Management and William C. Martin’s Raging Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!